"Bioassay Development and Automation"

08:00

08:30

Registration

08:30

08:35

Welcome by the Chairman of ELRIG.de e.V.

Tobias May

Elrig.de e.V.

08:35

09:05

Keynote presentation: Applying AI and Automation to Improve Drug Design

Ola Engkvist

AstraZeneca, Mölndal, S

09:05

09:25

Activity is the key – Development of potency assays for biologics

Wilhelm Alexander Mengel

Abbvie, Ludwigshafen, D

09:25

09:45

Large scale phenotypic screen on 3-D organotypic models of cancer’

Nil Ege

ICR, London, UK

09:45

10:05

Bi-specific Antibodies - A Platform Approach for Lead Generation and Screening in Final Format

Georg Fertig

Roche, Penzberg, D

10:05

10:30

Coffee break & Poster session

10:30

10:50

Cell Based Acoustic Liquid Handling: transfer from 96 to 384 well format

Paula Urquhart

Covance, Harrogate, UK

10:50

11:10

Automation of Potency Assays:
it’s not plug-and-play, it’s a journey   

Hermann Beck

Roche, Basel, CH

11:10

11:30

Cell Based Assays and Automation - When details become obstacles

Mario Graeve

Fraunhofer IPA, Stuttgart, D

11:30

11:50

Encoded Library Technologies as Integrated Lead Finding Platforms for Drug Discovery

Johannes Ottl

Novartis, Basel, CH

11:50

12:10

Development of lead molecules for antibody therapies

André Frenzel

Yumab, Braunschweig, D

12:10

13:50

Lunch Break & Poster Session

13:50

14:10

From Sample to Result - Full-Automation of Potency Assays

Katharina Künzel

Boehringer Ingelheim, Biberach, D

14:10

14:30

Anticalins: From concept molecules to clinical candidates

Rachida Bel Aiba

Pieris Pharmaceuticals, Freising, D

14:30

14:50

Automation-enabled assay development for high throughput screening

Nina Großmann

Merck, Darmstadt, D

14:50

15:10

Deep sequencing analysis of antibody phage display selection outputs: Leaving conventional screening behind

Stefan Ewert

Novartis, Basel, CH

15:10

15:30

Bioactivity Assays & GMP

Ulrike Herbrand

Charles River, Erkrath, D

15:30

15:50

Coffee break & Poster session

15:50

16:10

Innovative Strategies for Antibody Lead Discovery and Optimization

Ernst Weber

Bayer, Leverkusen, D

16:10

16:20

Snapshot: Turning Cells into Reagents – what makes a cell assay ready?

Oliver Wehmeier

Accellerate, Hamburg, D

16:20

16:40

Bioassays for the detection of neutralizing antibodies against AAV – Strategies and Concepts

Arno Kromminga

Bioagilytix, Hamburg, D

16:40

16:50

Snapshot: Promega Bridging of ADCC Reporter Bioassay with improved PBMC-based ADCC Cytotoxicity Assay

Axel Johann

Promega, Mannheim, D

16:50

17:00

Snapshot:

Martin Theiss

Nexcelom, Manchester, UK

17:00

Wrap up Forum 2020